PCGF1 Promotes the Tumorigenesis of Malignancies Through Upregulating CCDC34 in Glioma.
8 affiliations
- 1Department of Neurosurgery, Third Xiangya Hospital, Central South University, Changsha, Hunan, China.
- 2Hunan Provincial University Key Laboratory of the Fundamental and Clinical Research on Neurodegenerative Diseases, Changsha Medical University, Changsha, Hunan, China.
- 3Department of Emergency, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- 4National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- 5Department of Neurosurgery, The First Affiliated Hospital of University of South China, Hengyang, Hunan, China.
- 6Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
- 7Department of Neurosurgery, First Affiliated Hospital of Jishou University, Jishou, Hunan, China.
- 8Department of Neurosurgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde, Hunan, China.
Abstract
Background
Polycomb group factor 1 (PCGF1) and coiled-coil domain-containing protein 34 (CCDC34) have been implicated in tumorigenesis in multiple malignancies. However, their biological functions and prognostic significance in glioma remain poorly defined.Methods
RNA-sequencing data from glioma cell lines with PCGF1 knockdown were obtained from the GEO database. Correlations between PCGF1 and CCDC34 expression were analyzed using datasets from TCGA, CGGA, and GEO. In addition, RT-qPCR was performed to quantify PCGF1 and CCDC34 expression in glioma specimens. Kaplan-Meier survival analyses were conducted to evaluate the prognostic value of CCDC34. Functional assays were performed using cell lines with PCGF1 or CCDC34 knockdown and overexpression to assess their roles in glioma progression and to elucidate their regulatory relationship. Cell proliferation and colony formation assays were carried out to evaluate tumorigenic capacity.Results
CCDC34 expression was significantly downregulated in glioma cell lines following PCGF1 knockdown compared with controls. CCDC34 expression positively correlated with WHO tumor grade in glioma. Elevated CCDC34 expression was significantly associated with poorer patient outcomes. Functionally, CCDC34 expression was closely linked to enhanced cell proliferation and colony-forming ability. Rescue experiments demonstrated that PCGF1 promotes glioma cell proliferation in a CCDC34-dependent manner. Gene set enrichment analysis (GSEA) further revealed that both PCGF1 and CCDC34 expression were positively associated with hypoxia, coagulation, and epithelial-mesenchymal transition (EMT) signaling pathways.Conclusion
Our findings demonstrate that PCGF1 promotes glioma proliferation in a CCDC34-dependent manner and suggest that CCDC34 may serve as a novel prognostic biomarker and potential therapeutic target in glioma.
Related
- UPF1-mediated mRNA decay promotes melanoma tumorigenesis through miR-101-3p-dependent destabilization of NANOS1.
- Prenatal low-dose cesium-137 exposure combined with a lipid-enriched diet promotes late-onset hepatic tumorigenesis in male mouse offspring
- Oncogenic CLDN1 promotes thyroid cancer progression through TAp63-mediated glycolytic switching
- RNA polymerase I inhibitor BMH-21 promotes mutant p53 reactivation through nuclear zinc mobilization
- CDCA5 promotes hepatocellular carcinoma progression by suppressing ferroptosis through PP2Ac/p53/STEAP3 signaling
BibTeX
@article{chen2026pcgf1,
title = {{PCGF1 Promotes the Tumorigenesis of Malignancies Through Upregulating CCDC34 in Glioma.}},
author = {Yuanbing Chen and Jianbing Xiong and Ziran Ou and Tianhao Zhao and Hui Li and Jun Huang and Zhi Tian and Wuyang Cao},
journal = {Annals of clinical and translational neurology},
year = {2026},
month = oct,
doi = {10.1002/acn3.70559},
url = {https://europepmc.org/article/MED/42908110},
note = {CC BY},
}
RIS
TY - JOUR
TI - PCGF1 Promotes the Tumorigenesis of Malignancies Through Upregulating CCDC34 in Glioma.
AU - Yuanbing Chen
AU - Jianbing Xiong
AU - Ziran Ou
AU - Tianhao Zhao
AU - Hui Li
AU - Jun Huang
AU - Zhi Tian
AU - Wuyang Cao
PY - 2026
DA - 2026/10/21
JO - Annals of clinical and translational neurology
DO - 10.1002/acn3.70559
UR - https://europepmc.org/article/MED/42908110
AB - Background Polycomb group factor 1 (PCGF1) and coiled-coil domain-containing protein 34 (CCDC34) have been implicated in tumorigenesis in multiple malignancies. However, their biological functions and prognostic significance in glioma remain poorly defined.Methods RNA-sequencing data from glioma cell lines with PCGF1 knockdown were obtained from the GEO database. Correlations between PCGF1 and CCDC34 expression were analyzed using datasets from TCGA, CGGA, and GEO. In addition, RT-qPCR was performed to quantify PCGF1 and CCDC34 expression in glioma specimens. Kaplan-Meier survival analyses were conducted to evaluate the prognostic value of CCDC34. Functional assays were performed using cell lines with PCGF1 or CCDC34 knockdown and overexpression to assess their roles in glioma progression and to elucidate their regulatory relationship. Cell proliferation and colony formation assays were carried out to evaluate tumorigenic capacity.Results CCDC34 expression was significantly downregulated in glioma cell lines following PCGF1 knockdown compared with controls. CCDC34 expression positively correlated with WHO tumor grade in glioma. Elevated CCDC34 expression was significantly associated with poorer patient outcomes. Functionally, CCDC34 expression was closely linked to enhanced cell proliferation and colony-forming ability. Rescue experiments demonstrated that PCGF1 promotes glioma cell proliferation in a CCDC34-dependent manner. Gene set enrichment analysis (GSEA) further revealed that both PCGF1 and CCDC34 expression were positively associated with hypoxia, coagulation, and epithelial-mesenchymal transition (EMT) signaling pathways.Conclusion Our findings demonstrate that PCGF1 promotes glioma proliferation in a CCDC34-dependent manner and suggest that CCDC34 may serve as a novel prognostic biomarker and potential therapeutic target in glioma.
SN - 2328-9503
ER -